Inicio・Lista de Acciones・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Abierto

SectorSanidad

49.74 9.61

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

44.21

Máximo

48.35

Métricas clave
By Trading Economics
Ingresos	2.8M -13M
Ventas	-15M 151M
BPA	0.07
Margen de beneficios	-8.93
Empleados	1,178
EBITDA	19M -937K

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	-5.7% downside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	3.2B 6B
Apertura anterior	40.13
Cierre anterior	49.74

Noticias sobre sentimiento de mercado

By Acuity

100%

329 / 340 Clasificación en Healthcare

10X Genomics Inc (Class A) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 ago 2026, 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5 ago 2026, 19:26 UTC

Correlated Moves

News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3 ago 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31 jul 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30 jul 2026, 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29 jul 2026, 19:27 UTC

Macro Event

News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28 jul 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27 jul 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24 jul 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 jul 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 jul 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 jul 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 jul 2026, 19:16 UTC

News

Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Comparación entre iguales

Cambio de precio

10X Genomics Inc (Class A) previsión

Precio Objetivo

By TipRanks

-5.7% descenso

Estimación a 12 Meses

Media 43 USD -5.7%

Máximo 53 USD

Mínimo 23 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para 10X Genomics Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para 10X Genomics Inc (Class A) Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.